Emergency hospital admissions for people with MS are on the rise, according to new research published today by the MS Trust and Wilmington Healthcare. These cause distress for people with MS and cost the NHS millions, yet many of them could be avoided.
MS Trust names first sites in specialist nurse funding programme and announces plans to fund a further six new posts in the next year
The Scottish Medicines Consortium (SMC) has approved Zinbryta (daclizumab) as a treatment for relapsing remitting multiple sclerosis on the NHS in Scotland.
Ocrelizumab (Ocrevus) has become the first medicine to be licensed for primary progressive MS by the FDA (Food and Drug Administration), the American drug regulators. The FDA has also licensed ocrelizumab as a treatment for relapsing remitting MS.
NICE (National Institute for Health and Care Excellence) has approved Zinbryta (daclizumab) as a treatment for relapsing remitting multiple sclerosis on the NHS in England and Wales.
Two new reports published this week have highlighted the problems facing people trying to access neurological services in the UK
Researchers have discovered a protein that encourages the regrowth of myelin and may lead to new types of treatment for MS in the future
Canadian researchers have presented preliminary results from a clinical study which suggest that surgical treatment to unblock veins draining the brain and spinal cord is not effective in treating MS.
Two recently published studies have reported data on levels of disability in people with MS five years after receiving stem cell transplants.